There are currently no guidelines for the management of edema associated with<unk>  syndrome. The slow reversal of edema is important at a rate of 0.5-1 kg daily to prevent electrolyte disturbances, hypotension, ischemic acute tubular necrosis, and hemoconcentration associated with aggressive diuretic therapy. Since proteinuria is one of the most significant factors for progression of a disease and is associated with outcome, treatment of proteinuria in<unk>  syndrome must always be considered a priority. Angiotensin-converting enzyme inhibitors (ACE-I), with or without angiotensin-II receptor blockers (ARB) have been extensively studied and are well-known to decrease proteinuria and the risk of progression of renal disease in patients with<unk>  syndrome. Pneumococcal vaccines are recommended for all patients with<unk>  syndrome.
Nephrotic syndrome medical therapy
Acute tubular necrosis medical therapy
Interstitial nephritis medical therapy
Hepatorenal syndrome medical therapy
Goodpasture syndrome medical therapy
Renal amyloidosis medical therapy
Polycystic kidney disease medical therapy
Renal papillary necrosis medical therapy